• Isofol will host an Investor & Scientific Update in Stockholm on Nov. 12, 2026.
• Session will cover recent progress on arfolitixorin, including data from an ongoing phase Ib/II colorectal cancer study.
• A follow-up investor meeting in Gothenburg on Nov. 13, 2026 will recap key messages from the Stockholm event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Isofol Medical AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.